Filing Details

Accession Number:
0000903423-18-000373
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-07-03 17:59:39
Reporting Period:
2018-07-02
Accepted Time:
2018-07-03 17:59:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1693415 Translate Bio Inc. TBIO Pharmaceutical Preparations (2834) X0
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1131399 Plc Glaxosmithkline 980 Great West Road
Brentford Middlesex X0 TW8 9GS
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-07-02 1,674,016 $0.00 1,674,016 No 4 C Indirect See Footnote
Common Stock Acquisiton 2018-07-02 1,300,116 $0.00 2,974,132 No 4 C Indirect See Footnote
Common Stock Acquisiton 2018-07-02 454,550 $0.00 3,428,682 No 4 C Indirect See Footnote
Common Stock Acquisiton 2018-07-02 269,230 $13.00 3,697,912 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2018-07-02 9,300,000 $0.00 1,674,016 $0.00
Common Stock Series B Preferred Stock Disposition 2018-07-02 7,222,797 $0.00 1,300,116 $0.00
Common Stock Series C Preferred Stock Disposition 2018-07-02 2,525,253 $0.00 454,550 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. S.R. One, Limited acquired 269,230 Common Stock of the Issuer in connection with the Issuer's initial public offering.
  2. The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
  3. The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").